Arbutus Biopharma (ABUS) has drawn investor attention after launching a modified Dutch Auction tender offer of up to US$230 million in stock repurchases, signaling a board approved plan to return capital.
The tender offer comes after a period of strong gains for Arbutus Biopharma, with a 30-day share price return of 18.72% and a year-to-date share price return of 9.01%. Total shareholder return over the past year is 42.47% and 156.16% over three years, suggesting momentum has been building as recent earnings and buyback news reshape how investors view the company’s prospects and risk profile.
Scan beyond Arbutus Biopharma and compare this buyback story with other stocks that screen well on balance sheet strength and fundamentals using our curated list of solid balance sheet and fundamentals (51 results)
For Arbutus Biopharma, a US$230 million tender offer at a premium to the last close can look like a vote of confidence in the business or a surge in sentiment. Which story do the current valuation markers support?
Price-to-Earnings of 6.7x: Is it justified?
On a headline measure, Arbutus Biopharma trades on a P/E of 6.7x, which looks low relative to broad US equities and many biotech peers at the last close of $5.20.
The P/E ratio compares the current share price with earnings per share and gives you a simple way to relate what you pay to what the company currently earns. For a clinical stage biopharma business that has only recently become profitable, a low P/E can reflect either cautious expectations for the durability of those earnings or limited confidence that recent profits will repeat.
Here, the picture is mixed. Arbutus Biopharma has recently moved into profitability and its return on equity is described as outstanding at 59.2%, and its earnings are assessed as high quality. Yet analyst forecasts point to declining revenue and earnings over the next three years, and the stock is described as expensive when compared with an estimated fair P/E of 1.3x. That suggests the current P/E of 6.7x is materially higher than the level some valuation models indicate the market could eventually move toward.
Against the wider US market P/E of 19.1x and the US biotech industry average of 17.8x, Arbutus Biopharma trades on a much lower multiple. The company is described as good value relative to both the market and its biotech peers on this simple comparison, yet expensive relative to its own estimated fair P/E, which points to a split reading of value depending on which benchmark investors prioritise.
For a deeper look at how that estimated fair P/E is calculated and where Arbutus Biopharma could screen as mispriced, check out the Explore the SWS fair ratio for Arbutus Biopharma
Result: Price-to-Earnings of 6.7x (ABOUT RIGHT)
However, Arbutus Biopharma still carries clear risks, including assessed revenue and net income declines, and the chance that upcoming trial results or licensing progress disappoint.
Find out about the key risks to this Arbutus Biopharma narrative.
Next Steps
With sentiment on Arbutus Biopharma clearly mixed, you might want to move quickly and review the data for yourself. To weigh the concerns against the potential positives in one place, start with our breakdown of 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Arbutus Biopharma?
If Arbutus Biopharma has caught your attention, do not stop there. Broaden your watchlist with fresh stock ideas that match different risk and return profiles.
- Target potential mispricing by checking companies that currently look out of favour yet financially resilient through the 49 high quality undervalued stocks.
- Build a steadier income stream by reviewing stocks that offer higher yields and consistent payouts via the 12 dividend fortresses.
- Prioritise resilience by focusing on companies that show stronger balance sheets and fundamentals using this curated list of solid balance sheet and fundamentals (51 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com